{"schema_version":"secwatch.filing_event.v1","accession":"0001576885-24-000032","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2024-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.676969+00:00","generated_at":"2026-06-06T11:05:31.810042+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Acumen appoints Dr. James Doherty as President and Chief Development Officer","bullets":["Dr. James Doherty appointed President and Chief Development Officer effective Feb 1, 2024, reporting to CEO Daniel O'Connell.","Doherty previously served as Chief Development Officer at Sage Therapeutics, contributing to two FDA approvals for postpartum depression.","He will oversee clinical/non-clinical development, CMC, and regulatory functions as Acumen prepares to initiate ALTITUDE-AD study for ACU193.","Daniel O'Connell's title changes to CEO (previously CEO and President) as Doherty assumes the President role.","Doherty led Alzheimer's research at AstraZeneca and holds a Ph.D. in Neurobiology from Georgetown University."],"urls":{"canonical":"https://secwatch.observer/filing/0001576885-24-000032","json":"https://secwatch.observer/filing/0001576885-24-000032.json","markdown":"https://secwatch.observer/filing/0001576885-24-000032.md","text":"https://secwatch.observer/filing/0001576885-24-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000157688524000032/0001576885-24-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000157688524000032/abos-20240201.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T11:05:31.810042+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4b5fe28401","claim":"James Doherty was appointed as President and Chief Development Officer at Acumen Pharmaceuticals, Inc..","evidence_excerpt":"James Doherty has been appointed as its President and Chief Development Officer, effective February 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576885/000157688524000032/0001576885-24-000032-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Development Officer"}],"fact_type":"executive_change"},{"claim_id":"b96b5682b8","claim":"Daniel O'Connell changed role as Chief Executive Officer at Acumen Pharmaceuticals, Inc..","evidence_excerpt":"Effective upon the commencement of Mr. Doherty's employment, Daniel O'Connell's position would be updated to Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576885/000157688524000032/0001576885-24-000032-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"updated"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}